The prevalence and high cost of MV have led to the development of many processes aimed at reducing its duration, including sedation interruption (8, 9), evidence-based liberation protocols (10, 11) , and bundles to prevent ventilator-associated pneumonia (12). Other interventions aimed at reducing duration of MV include early mobilization (13, 14) , physiotherapy (15), and tracheotomy (16, 17) .
Objectives: To develop a model that predicts the duration of mechanical ventilation and then to use this model to compare observed versus expected duration of mechanical ventilation across ICUs. Design: Retrospective cohort analysis. Setting: Eighty-six eligible ICUs at 48 U.S. hospitals. Patients: ICU patients receiving mechanical ventilation on day 1 (n = 56,336) admitted from January 2013 to September 2014. Interventions: None.
Measurements and Main Results:
We developed and validated a multivariable logistic regression model for predicting duration of mechanical ventilation using ICU day 1 patient characteristics. Mean observed minus expected duration of mechanical ventilation was then obtained across patients and for each ICU. The accuracy of the model was assessed using R 2 . We defined better performing units as ICUs that had an observed minus expected duration of mechanical ventilation less than -0.5 days and a p value of less than 0.01; and poorer performing units as ICUs with an observed minus expected duration of mechanical ventilation greater than +0.5 days and a p value of less than 0.01. The factors accounting for the majority of the model's explanatory power were diagnosis (71%) and physiologic abnormalities (24%). For individual patients, the difference between observed and mean predicted duration of mechanical ventilation was 3.3 hours (95% CI, 2.8-3.9) with R 2 equal to 21.6%. The mean observed minus expected duration of mechanical ventilation across ICUs was 3.8 hours (95% CI, 2.1-5.5), with R 2 equal to 69.9%. Among the 86 ICUs, 66 (76.7%) had an observed mean mechanical ventilation duration that was within 0.5 days of predicted. Five ICUs had significantly (p < 0.01) poorer performance (observed minus expected duration of mechanical ventilation, > 0.5 d) and 14 ICUs significantly (p < 0.01) better performance (observed minus expected duration of mechanical ventilation, < −0.5 d).
Conclusions:
Comparison of observed and case-mix-adjusted predicted duration of mechanical ventilation can accurately assess and compare duration of mechanical ventilation across ICUs, but cannot accurately predict an individual patient's mechanical ventilation duration. There are substantial differences in duration of mechanical ventilation across ICU and their association with unit practices and processes of care warrants examination. (Crit Care Med 2016; 44:1042-1048) Key Words: duration of mechanical ventilation; intensive care unit; prediction; prolonged mechanical ventilation; resource utilization T he use of mechanical ventilation (MV) is frequent in ICUs, and patients who require MV account for a disproportionate amount of resource use (1) . Prolonged MV has most frequently been defined as greater than or equal to 96 hours, which is based on a Center for Medicare Services Diagnosis Related Group, although other definitions have been suggested (2) . Patients with prolonged MV are increasing in frequency (3, 4) , generate high acute care costs (5, 6) , and frequently receive care in post-acute care facilities (7).
The prevalence and high cost of MV have led to the development of many processes aimed at reducing its duration, including sedation interruption (8, 9) , evidence-based liberation protocols (10, 11) , and bundles to prevent ventilator-associated pneumonia (12) . Other interventions aimed at reducing duration of MV include early mobilization (13, 14) , physiotherapy (15) , and tracheotomy (16, 17) .
The ability to estimate the duration of MV for patient groups would be useful in assessing the cost and efficiency of MV. Critical care physicians, however, have a limited ability to predict the duration of ventilation during the first 48 hours (18) . Several studies have identified risk factors associated with a longer duration of MV (19) (20) (21) (22) , but none includes a model that predicts the actual duration of MV. Therefore, this study's objectives are 1) to use a multi-institutional clinical database to develop a model that predicts case-mix-adjusted duration of MV at the patient level, with predictors being those characteristics obtainable from an electronic medical record; and 2) to use that model to compare case-mix-adjusted duration of MV among ICUs.
METHODS
Data were obtained from the Acute Physiology and Chronic Health Evaluation (APACHE) Outcomes database (Cerner Corporation, Kansas City, MO) for ICU admissions from January 1, 2010, to September 30, 2014 . Participation in APACHE Outcomes is voluntary: participating ICUs pay a set fee for use of the software. The resultant database was generated based on records of medical care and collected using software that supports automated and computer-based manual entry. Patient data were stripped of personal identifiers in compliance with the Health Insurance Portability and Accountability Act. The study was submitted to the Institutional Review Board at Albert Einstein College of Medicine (Institutional Review Board; 2013-2602) and deemed exempt from review under federal regulation.
Institutional and Patient Data
The characteristics of each hospital and ICU were self-reported. Data on each patient during ICU day 1 were generated for consecutive unselected ICU admissions. Details about data collection, reliability, accuracy, and field use of the APACHE system have been previously described (23) (24) (25) . Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/ B667) shows the data elements collected for this study.
The study cohort included adult patients (≥ 16 yr old) who were placed on MV at any time during their first ICU day and received MV for at least 1 hour. Over 90% of patients placed on MV in the APACHE database have their first episode begin on day 1, and to serve as a benchmark we only used those episodes. We excluded patients remaining in ICU for less than 4 hours, and those with burns or missing clinical and outcome data, as APACHE does not use these patients for predictions. We also excluded patients admitted after coronary artery bypass surgery because their MV duration is significantly shorter than for other ICU patients. Patients from ICUs with less than 100 patients ventilated on day 1 were not included for the unit analysis, as these units were new to APACHE Outcomes and data quality was unknown. We did not examine care processes such as liberation protocols or practices such as early mobilization because this information was not available. Finally, we did not include patients who were receiving noninvasive ventilator support.
Duration of Ventilation and Outcome Measurement
We considered the first episode of MV to have concluded when the patient was liberated from the ventilator for at least 2 hours, regardless of whether or not the patient was subsequently placed back on MV. This was done to avoid counting spontaneous breathing trials off the ventilator as an end to MV. If reinstitution of MV occurred within 2 hours, then the two durations of MV were combined into a single episode. Duration was calculated using the number of minutes from initiation to completion of MV (not including 2 hr post ventilation) and converted to days and fractions of days. This analysis did not account for ICU survivors receiving MV when transferred to another hospital or post-acute care facility. Thus, death and transfer while on MV were also defined as end points for duration of ventilation. Outcomes included duration of ventilation, ICU and hospital mortality, and lengths of stay.
Analysis of Factors Determining Duration of Ventilation
We split the cohort into two groups; the group used to develop the model consisted of admissions from 2010 to 2012, while admissions from 2013 to 2014 were used as the validation dataset. To create a model that predicted duration of MV, we performed a fixed-effects multivariable linear regression. Because duration of MV is highly skewed, patients with a duration of MV greater than 14 days were recorded as 14 days. Truncation at 14 days was chosen as it accounts for 94.8% of all MV episodes in our dataset (Fig. 1) . Next, duration of MV was logtransformed using (duration + 1). The log term (duration + 1) was used as a large percentage of patients had duration of MV less than 1 day, which would result in negative values. This made duration of MV normally distributed.
The candidate predictor variables were selected based on data collected for APACHE IV (24) and the results of prior studies (19, 26, 27) , and are shown in Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/ B667). All variables were entered into a multiple linear regression formula to predict log (MV duration + 1.0). The Acute Physiology Score (APS) had three cubic spline terms added (knots at 10, 22, and 32) as did age (knots at 27, 51, and 64), while the square root of hospital length of stay (LOS) before ICU admission had two spine terms added (knots at 0.121 and 0.423). There were also two interaction terms for the binary variable of a patient having severe chronic obstructive pulmonary disease (COPD), one with age and another with the APS; these were chosen a priori due to our belief that COPD was a serious comorbidity for ventilated patients, and that its severity probably was affected by age as well as APS. All potential predictors were included in the initial model. Variables were then eliminated using a backwards stepwise approach if their marginal p value was less than 0.10. For variables with more than one level (e.g., diagnostic group), we removed those groups whose marginal p value was less than 0. 10 . Mean values at the patient level were obtained for observed and predicted duration of MV, then converted back into their original units (d) using the formula (exp x -1), where x is the transformed value of duration of MV as defined above. Model accuracy across patients was assessed using the mean observed minus expected (i.e., predicted) duration of MV (OMEMV) across patients, as well as the R 2 of observed and expected duration of MV.
Subgroup Analysis
We performed subgroup analyses to evaluate the model's performance in more homogenous patient populations. First, we examined the model's performance among patients with the six most frequent ICU admission diagnoses. Second, we assessed the impact of ICU survival or death on duration of ventilation by dividing patients as to whether or not they survived or died at ICU discharge, and then assessed the OMEMV for each subgroup. The above analyses were undertaken because these factors have previously been shown to impact the accuracy of predictions of ICU resource use (28, 29) .
Comparison of Adjusted Duration of Ventilation Across ICUs
We calculated the observed and the predicted duration of ventilation (transformed as described above) for each patient in the validation cohort, and calculated the mean value of both metrics for each ICU. To compare the efficiency of MV use across ICUs, we examined the mean OMEMV for each unit.
We also calculated the R 2 for mean observed and mean predicted MV across units.
To identify better performing units, we prespecified that an ICU had to have an OMEMV less than − 0.5 days and a p value of less than 0.01. Poorer performing units were those ICUs with an OMEMV greater than 0.5 days and a p value of less than 0.01.
RESULTS
There were 202,598 admissions in 139 ICUs at 60 hospitals from January 1, 2010, to September 30, 2014. Among these admissions, 63,394 were patients placed on MV during ICU day 1. After exclusion criteria were applied, 58,279 patients remained. When ICUs with less than 100 patients receiving MV on day 1 were excluded, there were 56,336 admissions in 86 ICUs at 48 hospitals. Table 1 shows the characteristics of the ICUs and hospitals included for analysis. Hospitals were well represented across geographic regions, bed size, and academic status. Table 2 gives the characteristics of the 56,336 eligible admissions, broken down by inclusion in the development or validation datasets. There were few meaningful differences between the two groups, the exceptions being: having greater than or equal to one chronic health item (40.7% in development set vs 51.5% in validation set), being on MV within 1 hour of ICU discharge (20.7% in development set vs 16.4% in validation set), and mean hospital LOS (13.5 d in development set vs 12.7 d in validation set).
The top six diagnoses in the development dataset in descending order were cardiac arrest, sepsis of pulmonary source, cardiac valve surgery, drug overdose, COPD, and bacterial pneumonia. The same six diagnoses also had the highest frequency in the validation dataset, although in slightly different order: cardiac arrest, sepsis of pulmonary source, drug overdose, bacterial pneumonia, cardiac valve surgery, and COPD. These diagnoses accounted for 28% of all admissions. Figure 1 shows the frequency distribution of duration of MV, truncated at 30 days. The distribution was highly skewed with a mean of 3.62 (± 0.02) days when compared with a median of 1.63 days (interquartile range, 0.64-4.34 d).
Appendix Table 1 (Supplemental Digital Content 2, http:// links.lww.com/CCM/B668) gives the individual coefficients, ses, and p values for each of the variables in the final model. Only gender and admission source had a p value of greater than 0.10 and were subsequently removed. Figure 2 shows the percentage of the total variance in duration of MV accounted for by broad variable categories in the predictive model. Diagnosis (n = 102) was the most influential category, accounting for 71.3% of the model's power, followed by physiology at 23.8%. Together, these two factors were responsible for 95.1% of variation explained by the predictive model. Demographics (2.4%), comorbidities (1.4%), and admission variables (0.9%) added little to the model's predictive power.
Across individual patients, the predictive model's R 2 was 21.6%, while across ICUs R 2 was 69.9%. When duration of MV was converted back to its original scale (d), the observed mean value across all patents was 2.13 days, while the predicted duration was 2.27 days, a difference of 0.14 days, that is, 3.3 hours (95% CI, 2.8-3.9). Across ICUs, the mean observed duration of MV was 2.14 days, while the mean predicted duration was 2.30 days, a difference of 3.8 hours (95% CI, 2.1-5.5).
For admissions with the top six diagnoses, mean observed MV duration was 2.23 days versus an expected MV duration of 2.37 days, a difference of 3.4 hours (95% CI, 0.7-6.0). There was no difference in OMEMV among the top six diagnostic groups, with the exception of patients admitted after a cardiac arrest: these patients had a significantly higher OMEMV. This would negatively impact only those ICUs whose patient casemix was predominantly comprised of patients admitted after a cardiac arrest, which does not occur in any ICU in this study.
When the validation dataset was stratified by whether or not the patient died before ICU discharge, mean observed duration of MV for survivors was 2.05 days, while mean predicted duration of MV was 2.16 days, and OMEMV was − 0.11 days: 2.6 hours (95% CI, 1.0-4.2). For patients who died before ICU discharge, observed MV duration was 2.49 days, mean predicted MV duration was 2.78 days, and OMEMV was − 0.29 days: 6.9 hours (95% CI, 3.4-10.2). Figure 2 shows the distribution of the OMEMV for each unit. Except for two outlier ICUs, the distribution was symmetrical. Of the 86 ICUs, 66 (76.7%) had an observed mean duration of MV that was within 0.5 days of that predicted; 35 (40.1%) were within 0.25 days (i.e., 6 hr). Supplemental Figure 1 (Supplemental Digital Content 1, http://links.lww. com/CCM/B667) displays a funnel plot for the mean OMEMV across units. From the figure, it is clear that a few ICUs were significant (as shown by points outside of the confidence bounds), which was not due solely to having a large number of admissions (i.e., large values on the x-axis).
There were five ICUs (5.8%) that had an OMEMV greater than 0.5 days and a p value of less than 0.01: these were poorer performing units. Conversely, there were 14 ICUs (16.3%) that had an OMEMV less than − 0.5 days and a p value of less than 0.01: these were better performing units. These performance outliers had rates multiple episodes of MV of 5.9% and 5.7%, respectively, similar to the overall rate of 5.8%. As shown in Supplemental Table 2 (Supplemental Digital Content 1, http:// links.lww.com/CCM/B667), mean ICU mortality rates were lowest in the five best-performing units (lowest OMEMV) and higher in the 14 worst-performing units (highest OMEMV).
DISCUSSION
Using variables that are collected electronically, we developed and validated a model to predict the duration of MV. For patients in the validation dataset, the difference between observed and expected duration of MV was only 3.3 hours. Since the model's accuracy was similar in both the development and validation dataset (the latter had more recent ICU admissions), our results also suggest that the relationship between patient characteristics and MV duration has not changed over the course of this study. Results were similar for the top six diagnoses and when stratifying by vital status at ICU discharge. The R 2 of 21.6% across individuals, however, connotes considerable unexplained variation in prediction, suggesting that the model is of limited use for predicting duration of MV for individual patients.
Across ICUs, the difference between observed and expected duration of MV was 3.8 hours, with an R 2 of 69.9%. Additionally, 66 of 86 ICUs (77%) had an observed duration of MV that was within 12 hours of the expected duration. These findings suggest that duration of MV can be predicted for use in comparative benchmarking across ICUs. Using a predefined metric that combined OMEMV and p value, we were able to identify five units performing worse than expected, as opposed to 14 units performing better than expected. A perfectly calibrated model would have the same number of units performing better and worse than expected, which indicates that, while the current model is adequate for benchmarking, there is room for improvement. Compared to previously reported models (19) (20) (21) (22) , our model is more robust in predicting mean duration of MV across patient groups and ICUs. Predicting duration of MV has many parallels to our previously published APACHE IV ICU LOS predictions (28, 29) . Both measures are highly skewed to the right, necessitating a log transform before modeling. Predictive accuracy at the top decile is also difficult, which is why we truncated the MV duration to 14 days and previously truncated ICU LOS at 30 days. We chose to truncate MV duration rather than delete those patients, as outlier durations were not randomly distributed across ICUs. Finally, the predictor variables for the two outcomes are similar, but their relative contributions differ; diagnosis has a greater influence on duration of MV (71%) than on ICU LOS (17%) and physiologic abnormalities a smaller influence on duration of MV (24%) than on ICU LOS (50%).
Our subgroup analysis did not show a substantial difference in OMEMV between patients who survived to hospital discharge versus those who died before discharge. Thus ICUs with a high mortality rate do not necessarily have a low OMEMV. The converse is also accurate: hospitals with a low OMEMV had a lower ICU mortality than other sites. Future studies that include information about ICU structure and processes will be required to explain these findings.
Predicting the duration of MV can assist critical care practice in several ways: measuring an ICU's observed versus average case-mix adjusted duration of MV allows hospitals and ICUs to assess and compare their data to a multi-institutional standard. Using this comparison data, ICU leaders can examine the adequacy of their protocols (sedation use, liberation from MV, ventilator bundles, etc.) and practices (intensivist leadership, multidisciplinary teamwork). Objective predictions for patient groups might also prove useful in selecting patients for early mobilization (13, 14) , physiotherapy (15) , and tracheotomy (16, 17) .
In the future, comparison of care processes in combination with ICU level benchmarks for duration of MV could result in identification of best practices (30) . The use of case-mix adjustment for duration of MV might also be helpful in enhancing comparisons across clinical trials by reducing problems of variability in outcome selection, measurement, and reporting (31) . The model could also be used to further examine the relationship between volume and MV duration. Our study has several limitations. First, the ICUs were all located in the United States, limiting the model's generalization to other countries. Second, we did not model MV duration as a mixed-effects model, that is, with hospitals and ICUs as nested clusters, because we were interested in creating a general predictive model, rather than examining factors influencing MV duration. A study by Cohen et al (32) using data from the National Surgical Quality Improvement Program showed that hierarchical models and fixed effects logistic regression gave nearly identical results, with the latter being preferred for ease of implementation. Thus we went with the simpler fixed-effects model. Third, coronary artery bypass graft patients were excluded as their care paths and outcomes are markedly different from other critically ill patients. However, we elected to include patients admitted after cardiac valve surgery, whose outcomes might also be considered different and less adverse than for other diagnostic groups. In our study, the model performed well for this group (data not shown). Fourth, our use of 2 hours to designate ventilator liberation might be too restrictive, as it does not address airway issues or the need to reinstitute MV over the next 24-48 hours. Two hours off MV, however, is a useful and standardized way to capture one important aspect of the MV liberation process that can be reliably measured in multiple ICU populations. In addition, patients with more than one episode of MV tended to have prolonged second episodes (5.53 d), which is more indicative of liberation failure rather than a failed spontaneous breathing trial. However, patients with more than one episode of MV tended to have prolonged second episodes (mean, 5.53 d), which more aligns with liberation failure rather than a failed spontaneous breathing trial. This is what we assumed when creating our definition. Finally, we did not have information on implementation of lung protective ventilator strategies and other processes, which might have accounted for some of the variations in duration of MV among the ICUs. We also did not have information on removal of an artificial airway and partial ventilator support. Since many of these patients use noninvasive ventilation rather than an invasive ventilation, their number in this study is likely very low.
CONCLUSIONS
A model was developed that accurately predicts duration of MV. This allows for the comparison of case-mix adjusted predictions against the observed values for ICUs. The association of differences in an ICU's observed versus average case-mix adjusted duration of MV with unit practices and processes needs to be examined.
